Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs
NCT04852679
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
43
Enrollment
INDUSTRY
Sponsor class
Conditions
Gastroenteropancreatic Neuroendocrine Tumor
Interventions
DRUG:
Lanreotide autogel
Sponsor
Ipsen